Cannabis Stocks Decline Amid Profit-Taking Despite Potential Federal Reclassification
Cannabis stocks fell on Monday as investors took profits following a record-setting session, despite President Trump's confirmation of considering an executive order to reclassify marijuana.
On Monday, cannabis stocks declined as investors took profits following a record-setting session, despite President Donald Trump's confirmation that he is considering an executive order to reclassify marijuana.
The Amplify Seymour Cannabis ETF (CNBS) experienced a significant drop, closing nearly 7% lower. This downturn followed a surge of more than 50% on Friday, driven by reports that the president was contemplating reclassifying marijuana.
When asked about the potential executive order on Monday, President Trump stated, "We are considering that." He elaborated, "A lot of people want to see it [the reclassification], because it leads to tremendous amounts of research that can't be done unless you reclassify."
The proposed reclassification would move marijuana from a Schedule I substance, which includes drugs like heroin, to a Schedule III category, alongside substances such as steroids and Tylenol with codeine. This change is anticipated to facilitate research and potentially attract more investment to the cannabis industry.
Despite the president's comments, major cannabis companies saw their stock prices decline on Monday. Tilray Brands Inc. (TLRY) fell by 10%, Canopy Growth Corporation (CGC) decreased by 4.6%, and SNDL Inc. (SNDL) tumbled more than 13%.
Industry leaders have expressed cautious optimism regarding the potential reclassification. Tilray CEO Irwin Simon commented, "I'm a lot more optimistic than I ever have been."
The cannabis sector remains volatile as investors react to evolving federal policies and market dynamics.
Source
CNBCFact-checking
Fact-check the facts of the article using external sources and databases.